Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT02180711. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Study identification
- NCT ID
- NCT02180711
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Acerta Pharma BV
- Industry
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Interventions
- Lenalidomide Drug
- acalabrutinib Drug
- rituximab (IV) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 28, 2014
- Primary completion
- Aug 24, 2023
- Completion
- Dec 28, 2028
- Last update posted
- Oct 14, 2025
2014 – 2028
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85719 | — |
| Research Site | Downey | California | 90241 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Fountain Valley | California | 92708 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Coral Gables FL | Florida | 33146 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Louisville | Kentucky | 40207 | — |
| Research Site | New Orleans | Louisiana | 70112 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Morristown | New Jersey | 07960 | — |
| Research Site | Hawthorne | New York | 10532 | — |
| Research Site | Lake Success | New York | 11042 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Greenville | South Carolina | 29615 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | San Antonio | Texas | 78217 | — |
| Research Site | Temple | Texas | 76508 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
| Research Site | Spokane | Washington | 99208 | — |
| Research Site | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02180711, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02180711 live on ClinicalTrials.gov.